MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.

This will strengthen and improve the continuum of care cascade for patients with liver disease(s) and holds the potential to alleviate the cost burden of disease; and increase quality of life for patients following DAAs treatment.